These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 591447)

  • 1. Synthesis and antibacterial activities of 1-N [(S)-omega-amino-2-hydroxyalkyl] kanamycin A derivatives.
    Richardson K; Jevons S; Moore JW; Ross BC; Wright JR
    J Antibiot (Tokyo); 1977 Oct; 30(10):843-6. PubMed ID: 591447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and antibacterial activity of 1-N-(1,3-dihydroxy-2-propyl)kanamycin B (UK-31,214).
    Richardson K; Brammer KW; Jevons S; Plews RM; Wright JR
    J Antibiot (Tokyo); 1979 Oct; 32(10):973-7. PubMed ID: 528375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental study of the antibacterial activity and chemotherapeutic effectiveness of amikacin sulfate].
    Lobuseva AN; Kuznetsova SM; Samoĭlova LN
    Antibiot Med Biotekhnol; 1985 Oct; 30(10):776-80. PubMed ID: 4091515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The antibacterial activity of amikacin in comparison with four other aminoglycoside antibiotics (proceedings)].
    Schassan HH
    Zentralbl Bakteriol Orig A; 1976 Aug; 235(1-3):320-8. PubMed ID: 983520
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of amikacin sulfate (Amikin). A new aminoglycoside antibiotic.
    Schiffman DO
    JAMA; 1977 Oct; 238(14):1547-50. PubMed ID: 578232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics.
    Finland M; Garner C; Wilcox C; Sabath LD
    J Infect Dis; 1976 Nov; 134 SUPPL():S297-307. PubMed ID: 825588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer aminoglycosides--amikacin and tobramycin: an in-vitro comparison with kanamycin and gentamicin.
    Reynolds AV; Hamilton-Miller JM; Brumfitt W
    Br Med J; 1974 Sep; 3(5934):778-80. PubMed ID: 4213265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of amikacin and ten other aminoglycoside antibiotics against gentamicin-resistant bacterial strains.
    Reyonolds AV; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S291-6. PubMed ID: 62815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of bactericidal effects of four aminoglycoside antibiotics: amikacin, gentamicin, kanamycin and tobramycin (author's transl)].
    Drugeon HB; Courtieu AL
    Ann Microbiol (Paris); 1979 Apr; 130A(3):331-43. PubMed ID: 114083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial agents--Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin.
    Brewer NS
    Mayo Clin Proc; 1977 Nov; 52(11):675-9. PubMed ID: 336988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of netilmicin, gentamicin, tobramycin and amikacin against glucose fermenting and nonfermenting bacteria.
    DiPersio JR; Krafczyk TL
    Chemotherapy; 1980; 26(5):323-33. PubMed ID: 7389428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuning the regioselectivity of the Staudinger reaction for the facile synthesis of kanamycin and neomycin class antibiotics with N-1 modification.
    Li J; Chen HN; Chang H; Wang J; Chang CW
    Org Lett; 2005 Jul; 7(14):3061-4. PubMed ID: 15987205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity and ototoxicity in guinea pigs, and nephrotoxicity in rats of arbekacin.
    Kurebe M; Yokota M; Niizato T; Kai F; Yoshida T; Okamoto R; Mitsuhashi S
    Arzneimittelforschung; 1986 Oct; 36(10):1511-7. PubMed ID: 3814212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycodiversification for the optimization of the kanamycin class aminoglycosides.
    Wang J; Li J; Chen HN; Chang H; Tanifum CT; Liu HH; Czyryca PG; Chang CW
    J Med Chem; 2005 Oct; 48(20):6271-85. PubMed ID: 16190754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antibacterial activity of 1-N-[(S)-ω-amino-2-hydroxyalkyl] derivatives of dibekacin, 5-deoxydibekacin, 3'-deoxykanamycin A and gentamicin B.
    Umemura E; Sakamoto Y; Takahashi Y; Miyake T
    J Antibiot (Tokyo); 2015 Jun; 68(6):421-3. PubMed ID: 25712399
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of glycodiversification: expedient synthesis and antibacterial evaluation of a library of kanamycin B analogues.
    Li J; Wang J; Czyryca PG; Chang H; Orsak TW; Evanson R; Chang CW
    Org Lett; 2004 Apr; 6(9):1381-4. PubMed ID: 15101747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglycoside antibiotics. XII. Effect of N-alkylation in kanamycin antibiotics.
    Nakagawa S; Toda S; Abe Y; Yamashita H; Fujisawa KI; Naito T; Kawaguchi H
    J Antibiot (Tokyo); 1978 Jul; 31(7):675-80. PubMed ID: 690002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.